Share Purchase Plan (SPP) Offer Documents
The launch of the SPP follows the recent announcement by Bluechiip of a $4.6 million equity placement. Bluechiip is committed to ensuring its loyal shareholders also have the opportunity to acquire shares at the same price as participants in the placement.
Pursuant to the SPP, Eligible Shareholders may apply to purchase up to A$30,000 worth of new fully paid ordinary shares in Bluechiip (New Shares) (subject to any scale back) at an issue price of 15 cents per New Share (Issue Price) without paying brokerage or other transaction costs. The Issue Price is the same price paid by investors in the placement announced to ASX on 24 October 2019 and represents a discount of 6.4% to the volume weighted average price of fully paid ordinary shares (Shares), calculated over the last 15 days on which sales of Shares were recorded on ASX before the day on which the SPP was announced.
To view the Share Purchase Plan, please visit:
About Bluechiip Ltd
Bluechiip Ltd (ASX:BCT) has developed a wireless tracking solution for the healthcare and life science, security, defence and manufacturing industries which represents a generational change from current methods such as labels (hand-written and pre-printed), barcodes (linear and 2D) and microelectronic integrated circuit (IC)-based RFID (Radio Frequency Identification).
The unique tag is based on MEMS technology and contains no electronics. The tag can either be embedded or manufactured into a storage product, such as vials or bags. Easy identification, along with any associated information from the tag such as temperature can be detected by a reader, which can also sense the temperature of the tagged items. The traditional identification technologies have significant limitations. Whereas a barcode requires a visible tag or line-of-sight optical scan, bluechiip(R) technology does not. Unlike labels, barcodes and RFID, the bluechiip(R) technology can sense the temperature of each item a tag is attached to, or embedded in.
The bluechiip(R) technology has initial applications in the healthcare industry particularly those businesses which require cryogenic storage facilities (biobanks and biorepositories). bluechiip(R) offers the only technology that enables accurate and reliable tracking of products including stem cells, cord blood, and other biospecimens. In addition to functioning in extreme temperatures, the bluechiip(R) tracking solution can survive autoclaving, gamma irradiation sterilization, humidification, centrifuging, cryogenic storage and frosting.
The bluechiip(R) technology has other healthcare applications in pathology, clinical trials and forensics. Several other key markets outside of healthcare include cold-chain logistics/supply chain, security/defence, industrial/manufacturing and aerospace/aviation.
Further information is available at http://www.bluechiip.com